ND0701, A Novel Formulation of Apomorphine for Subcutaneous Infusion, in Comparison to a Commercial Apomorphine Formulation: 28-Day Pharmacokinetic Study in Minipigs and a Phase I Study in Healthy Volunteers to Assess the Safety, Tolerability, Pharmacokinetics and Relative Bioavailability

ND0701, A Novel Formulation of Apomorphine for Subcutaneous Infusion, in Comparison to a... CNS Drugs (2018) 32:443–454 https://doi.org/10.1007/s40263-018-0512-x OR IGINAL RESEARCH ARTIC L E ND0701, A Novel Formulation of Apomorphine for Subcutaneous Infusion, in Comparison to a Commercial Apomorphine Formulation: 28-Day Pharmacokinetic Study in Minipigs and a Phase I Study in Healthy Volunteers to Assess the Safety, Tolerability, Pharmacokinetics and Relative Bioavailability 1 2 3 3 3 • • • • • Yuval Ramot Abraham Nyska Liat Adar Cecile Durlach Danny Fishelovitch 4 4 3 5 • • • • Giuseppe Sacco Rosa Anna Manno Sheila Oren Itay Perlstein Oron Yacobi-Zeevi Published online: 10 April 2018 Springer International Publishing AG, part of Springer Nature 2018 Abstract Results (1) Preclinical study: No systemic toxicity was Background Subcutaneous apomorphine is used for the observed in apomorphine-treated minipigs, but local skin treatment of Parkinson’s disease (PD); however, infusion site reactions were observed at the infusion sites. These effects reactions are a common adverse event (AE), which can lead were less frequent and less severe and recovery was more to treatment discontinuation. Apomorphine formulations that rapid for ND0701 compared with APO-go . (2) Phase I are more tolerable and convenient for use are needed. study: Both formulations were safe and well tolerated Objective Our aim was http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png CNS Drugs Springer Journals

ND0701, A Novel Formulation of Apomorphine for Subcutaneous Infusion, in Comparison to a Commercial Apomorphine Formulation: 28-Day Pharmacokinetic Study in Minipigs and a Phase I Study in Healthy Volunteers to Assess the Safety, Tolerability, Pharmacokinetics and Relative Bioavailability

Loading next page...
 
/lp/springer-journals/nd0701-a-novel-formulation-of-apomorphine-for-subcutaneous-infusion-in-ARq0sg9CDE
Publisher
Springer International Publishing
Copyright
Copyright © 2018 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Neurology; Psychopharmacology; Pharmacotherapy; Neurosciences; Psychiatry
ISSN
1172-7047
eISSN
1179-1934
D.O.I.
10.1007/s40263-018-0512-x
Publisher site
See Article on Publisher Site

Abstract

CNS Drugs (2018) 32:443–454 https://doi.org/10.1007/s40263-018-0512-x OR IGINAL RESEARCH ARTIC L E ND0701, A Novel Formulation of Apomorphine for Subcutaneous Infusion, in Comparison to a Commercial Apomorphine Formulation: 28-Day Pharmacokinetic Study in Minipigs and a Phase I Study in Healthy Volunteers to Assess the Safety, Tolerability, Pharmacokinetics and Relative Bioavailability 1 2 3 3 3 • • • • • Yuval Ramot Abraham Nyska Liat Adar Cecile Durlach Danny Fishelovitch 4 4 3 5 • • • • Giuseppe Sacco Rosa Anna Manno Sheila Oren Itay Perlstein Oron Yacobi-Zeevi Published online: 10 April 2018 Springer International Publishing AG, part of Springer Nature 2018 Abstract Results (1) Preclinical study: No systemic toxicity was Background Subcutaneous apomorphine is used for the observed in apomorphine-treated minipigs, but local skin treatment of Parkinson’s disease (PD); however, infusion site reactions were observed at the infusion sites. These effects reactions are a common adverse event (AE), which can lead were less frequent and less severe and recovery was more to treatment discontinuation. Apomorphine formulations that rapid for ND0701 compared with APO-go . (2) Phase I are more tolerable and convenient for use are needed. study: Both formulations were safe and well tolerated Objective Our aim was

Journal

CNS DrugsSpringer Journals

Published: Apr 10, 2018

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off